Charles River Laboratories International Inc logo

CRL - Charles River Laboratories International Inc Share Price

$237.4 2.4  1.0%

Last Trade - 5:33pm

Sector
Healthcare
Size
Large Cap
Market Cap Ā£8.69bn
Enterprise Value Ā£10.03bn
Revenue Ā£2.10bn
Position in Universe 760th / 6444
Bullish
Bearish
Unlock CRL Revenue
Momentum
Relative Strength (%)
1m -7.12%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.88%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 28th Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1,298 1,363 1,681 1,858 2,266 2,621 2,889 3,184 +15.1%
-11.3 +20.4 +8.6 +14.3 +14.3 +16.5 +37.5 +12.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 26 September 2020, CharlesRiver Laboratories Intl. Inc revenues increased 11% to$2.13B. Net income increased 29% to $221.1M. Revenuesreflect Discovery And Safety Assessment segment increase of14% to $1.34B, Manufacturing Support segment increase of 9%to $376.1M, Research Models segment increase of 2% to$414.5M, United States segment increase of 10% to $1.2B,Europe segment increase of 12% to $595.4M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CRL
Graphical History

Revenue

CRL Revenue Unlock CRL Revenue

Net Income

CRL Net Income Unlock CRL Revenue

Normalised EPS

CRL Normalised EPS Unlock CRL Revenue

PE Ratio Range

CRL PE Ratio Range Unlock CRL Revenue

Dividend Yield Range

CRL Dividend Yield Range Unlock CRL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CRL EPS Forecasts Unlock CRL Revenue
Profile Summary

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Directors
Last Annual December 28th, 2019
Last Interim September 26th, 2020
Incorporated February 3, 1994
Public Since June 23, 2000
No. of Shareholders: 90
No. of Employees: 17,100
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , S&P Composite 1500 ,
Exchange New York Stock Exchange
Shares in Issue 49,742,626
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CRL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CRL
Upcoming Events for CRL
Tuesday 9th February, 2021 Estimate
Q4 2020 Charles River Laboratories International Inc Earnings Release
Wednesday 5th May, 2021 Estimate
Q1 2021 Charles River Laboratories International Inc Earnings Release
Frequently Asked Questions for Charles River Laboratories International Inc
What is the Charles River Laboratories International Inc share price?

As of 5:33pm, shares in Charles River Laboratories International Inc are trading at $237.4, giving the company a market capitalisation of Ā£8.69bn. This share price information is delayed by 15 minutes.

How has the Charles River Laboratories International Inc share price performed this year?

Shares in Charles River Laboratories International Inc are currently trading at $237.4 and the price has moved by 61.63% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Charles River Laboratories International Inc price has moved by 37.33% over the past year.

What are the analyst and broker recommendations for Charles River Laboratories International Inc?

Of the analysts with advisory recommendations for Charles River Laboratories International Inc, there are there are currently 7 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Charles River Laboratories International Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Charles River Laboratories International Inc next release its financial results?

Charles River Laboratories International Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-26
What is the Charles River Laboratories International Inc dividend yield?

Charles River Laboratories International Inc does not currently pay a dividend.

Does Charles River Laboratories International Inc pay a dividend?

Charles River Laboratories International Inc does not currently pay a dividend.

When does Charles River Laboratories International Inc next pay dividends?

Charles River Laboratories International Inc does not currently pay a dividend.

How do I buy Charles River Laboratories International Inc shares?

To buy shares in Charles River Laboratories International Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopediaā€™s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Charles River Laboratories International Inc?

Shares in Charles River Laboratories International Inc are currently trading at $237.4, giving the company a market capitalisation of Ā£8.69bn.

Where are Charles River Laboratories International Inc shares listed? Where are Charles River Laboratories International Inc shares listed?

Here are the trading details for Charles River Laboratories International Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: CRL
What kind of share is Charles River Laboratories International Inc?

Based on an overall assessment of its quality, value and momentum, Charles River Laboratories International Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Charles River Laboratories International Inc share price forecast 2020?

Shares in Charles River Laboratories International Inc are currently priced at $237.4. At that level they are trading at 9.5% discount to the analyst consensus target price of 0.00.

Analysts covering Charles River Laboratories International Inc currently have a consensus Earnings Per Share (EPS) forecast of 7.853 for the next financial year.

How can I tell whether the Charles River Laboratories International Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Charles River Laboratories International Inc. Over the past six months, the relative strength of its shares against the market has been 16.03%. At the current price of $237.4, shares in Charles River Laboratories International Inc are trading at 24.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Charles River Laboratories International Inc PE Ratio?

The Charles River Laboratories International Inc PE ratio based on its reported earnings over the past 12 months is 36.29. The shares are currently trading at $237.4.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Charles River Laboratories International Inc?

Charles River Laboratories International Inc's management team is headed by:

James Foster - CHM
Stephen Chubb - IND
George Milne - LED
Robert Bertolini - IND
David Smith - CFO
William Barbo - EVP
Birgit Girshick - EVP
Joseph LaPlume - EVP
Nancy Andrews - IND
Who are the major shareholders of Charles River Laboratories International Inc?

Here are the top five shareholders of Charles River Laboratories International Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.89% (4.92m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 8.05% (4.01m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 3.56% (1.77m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.81% (1.40m shares)
iShares Core S&P Mid-Cap ETF Mutual Fund
Percentage owned: 2.6% (1.29m shares)
Similar to CRL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.